Amphastar subsidiary signs related-party supply deal with Letop; $0.6 million research cost increase
Amphastar's Chinese subsidiary ANP signed a five-year supply agreement with Nanjing Letop Biotechnology on March 3, 2026, for chemical intermediates, with no minimum purchase obligation. The company also amended a contract research agreement with Nanjing Hanxin, raising its total cost by about $0.6 million. Both counterparties are linked to the company's CEO and Chairman through family ownership, and the company states neither agreement is material to its financial condition or results of operations.
Key points
- Supply Agreement with Letop signed March 3, 2026, for five years; ANP has no minimum purchase obligation
- Contract Research Amendment with Hanxin raises total cost by about $0.6 million, shifting work from AMP-107 to AMP-105
- Letop and Hanxin are related parties; Audit Committee evaluated and approved both deals
- Company states neither agreement is material to its financial condition or results of operations
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.